Nipate
Forum => Kenya Discussion => Topic started by: vooke on October 01, 2021, 03:19:43 PM
-
Oct 1 (Reuters) - Merck & Co Inc's (MRK.N) experimental oral drug for COVID-19, molnupiravir, reduced by around 50% the chance of hospitalization or death for patients at risk of severe disease, according to interim clinical trial results announced on Friday.
Merck and partner Ridgeback Biotherapeutics plan to seek U.S. emergency use authorization for the pill as soon as possible, and to submit applications to regulatory agencies worldwide. Due to the positive results, the Phase 3 trial is being stopped early at the recommendation of outside monitors.
https://www.reuters.com/business/healthcare-pharmaceuticals/mercks-covid-19-pill-cuts-risk-death-hospitalization-by-50-study-2021-10-01/?taid=6156ea3f76ce46000139546f&utm_campaign=trueAnthem:+Trending+Content&utm_medium=trueAnthem&utm_source=twitter
-
@RV Kirgit, is this thing safe? 8)
-
@RV Kirgit, is this thing safe? 8)
Mapema sana
Si it's under trials?
-
https://assets-global.website-files.com/606d3dece4ec3c3866cc798a/60a5ff589cd77751eaf60c30_25%20The%20Israeli%20Peoples%20Committee%20Report.pdf
-
@RV Kirgit, is this thing safe? 8)
I bet Gen Sulk cannot touch things with 1ft pole.